Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M. Ángela Aznar"'
Autor:
Sara Labiano, Florinda Meléndez-Rodríguez, Asís Palazón, Álvaro Teijeira, Saray Garasa, Iñaki Etxeberria, M. Ángela Aznar, Alfonso R. Sánchez-Paulete, Arantza Azpilikueta, Elixabet Bolaños, Carmen Molina, Hortensia de la Fuente, Patricia Maiso, Francisco Sánchez-Madrid, Manuel Ortiz de Landázuri, Julián Aragonés, Ignacio Melero
Publikováno v:
OncoImmunology, Vol 6, Iss 4 (2017)
CD69 is an early activation marker on the surface of T lymphocytes undergoing activation by cognate antigen. We observed intense expression of CD69 on tumor-infiltrating T-lymphocytes that reside in the hypoxic tumor microenvironment and hypothesized
Externí odkaz:
https://doaj.org/article/9df43bea2bef4f4bbb379912e4099e72
Autor:
Ignacio Melero, Cristian Smerdou, Víctor Segura, Alfonso R. Sánchez-Paulete, Erkuden Casales, Inmaculada Rodriguez, Arantza Azpilikueta, Elixabet Bolaños, M. Ángela Aznar, Sara Labiano, José I. Quetglas
Supplementary figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88a99c63280e991cee9852c23efcd57b
https://doi.org/10.1158/2326-6066.22538054.v1
https://doi.org/10.1158/2326-6066.22538054.v1
Autor:
Ignacio Melero, Cristian Smerdou, Víctor Segura, Alfonso R. Sánchez-Paulete, Erkuden Casales, Inmaculada Rodriguez, Arantza Azpilikueta, Elixabet Bolaños, M. Ángela Aznar, Sara Labiano, José I. Quetglas
Supplementary figure 2. Effects of treatment with SFV-IL12 + anti-PD-1 combination on the B16.F10 and 4T1 tumor models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ef73a4d422461dd2725cc533e4077b9
https://doi.org/10.1158/2326-6066.22538057
https://doi.org/10.1158/2326-6066.22538057
Autor:
Ignacio Melero, Cristian Smerdou, Víctor Segura, Alfonso R. Sánchez-Paulete, Erkuden Casales, Inmaculada Rodriguez, Arantza Azpilikueta, Elixabet Bolaños, M. Ángela Aznar, Sara Labiano, José I. Quetglas
Virotherapy and checkpoint inhibitors can be combined for the treatment of cancer with complementarity and potential for synergistic effects. We have developed a cytolytic but nonreplicative viral vector system based on Semliki Forest virus that enco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::163f5e8d8139cd6a6b6d3110c47b193d
https://doi.org/10.1158/2326-6066.c.6548654.v1
https://doi.org/10.1158/2326-6066.c.6548654.v1
Autor:
Ignacio Melero, Cristian Smerdou, Víctor Segura, Alfonso R. Sánchez-Paulete, Erkuden Casales, Inmaculada Rodriguez, Arantza Azpilikueta, Elixabet Bolaños, M. Ángela Aznar, Sara Labiano, José I. Quetglas
Supplementary figure 1. Similar survival results with anti-PD-1 or anti-PD-L1 in the combination with SFV-IL12 for B16-OVA-derived tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0e9ff125e6c2f19940f47270553361
https://doi.org/10.1158/2326-6066.22538060
https://doi.org/10.1158/2326-6066.22538060
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marta Compte, Seandean Lykke Harwood, Ines G. Muñoz, Rocio Navarro, Manuela Zonca, Gema Perez-Chacon, Ainhoa Erce-Llamazares, Nekane Merino, Antonio Tapia-Galisteo, Angel M. Cuesta, Kasper Mikkelsen, Eduardo Caleiras, Natalia Nuñez-Prado, M. Angela Aznar, Simon Lykkemark, Jorge Martínez-Torrecuadrada, Ignacio Melero, Francisco J. Blanco, Jorge Bernardino de la Serna, Juan M. Zapata, Laura Sanz, Luis Alvarez-Vallina
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Cancer therapy using systemically administrated 4-1BB-targeting antibodies is often associated with severe toxicity due to the nonspecific activation of autoreactive T cells. Here, the authors have developed a trimeric antibody targeting both 4-1BB a
Externí odkaz:
https://doaj.org/article/7575acc4586f44568954b0510de1f6d3